The Liver Institute at Methodist Dallas — Dallas, Texas

The Liver Institute at Methodist Dallas is a clinical research site located in Dallas, Texas, United States 75203.

Crixeo Clinical Trials Trust Score: 20/100 (FAILING). This profile has not yet been claimed by the site owner.

The Liver Institute at Methodist Dallas has participated in 15 clinical trials with 4 currently active.

Therapeutic areas: Compensated Liver Cirrhosis, Metabolic Dysfunction Associated Steatohepatitis (MASH), Hepatitis C, Chronic.

Sponsors: Boehringer Ingelheim, Biolex Therapeutics, Inc., Genfit.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Dallas

Browse all research sites in Texas · View every site in Dallas

Sponsor Feasibility Report

Trust Score: 20/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for The Liver Institute at Methodist Dallas?

The Liver Institute at Methodist Dallas has a Crixeo Trust Score of 20/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has The Liver Institute at Methodist Dallas conducted?

The Liver Institute at Methodist Dallas has 15 clinical trials on record, with 4 currently active. Their work covers Compensated Liver Cirrhosis, Metabolic Dysfunction Associated Steatohepatitis (MASH), Hepatitis C, Chronic.

Is The Liver Institute at Methodist Dallas accredited by Crixeo Clinical Trials?

The Liver Institute at Methodist Dallas has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about The Liver Institute at Methodist Dallas?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.